

Citadel Europe LLP

MiFID II RTS 28 Best Execution Disclosure

Commodity Derivatives and Emission Allowances Derivatives – Futures and
Options Admitted to Trading on a Trading Venue (Transmitted)

April 2018

Quality of Execution Obtained on Execution Venues¹

Firm	Citadel Europe LLP	
Disclosure Period	1 January 2017 to 31 December 2017	
Publication Date	April 2018	
Class of instrument	Commodity Derivatives and Emission Allowances Derivatives – Futures and Options Admitted to Trading on a Trading Venue (Transmitted)	
	Summary of Analysis	Conclusion
Execution factors	<p>The relative importance of the execution factors was determined by the following execution criteria:</p> <ul style="list-style-type: none"> • the characteristics of the Citadel Fund • the characteristics of the order • the characteristics of the financial instrument to which the order related (e.g. liquidity); and • the characteristics of the broker or trading venue/systematic internaliser/market maker/liquidity provider/ third country entity performing a similar function to which the order could be directed. 	<p>The Firm considered liquidity and cost to be the most important execution factors when assessing quality of execution. No issues were noted with the relative importance given to the execution factors during the period under review.</p>
Close links, conflicts of interest and common ownership with respect to execution venues²	<p>Close links During the period under review certain orders were transmitted to the affiliate firm Citadel Advisors LLC to facilitate execution. These orders related to non-EMEA instruments.</p>	<p>Close links These close links did not influence the Firm's selection of the execution venues as the Firm followed its Best Execution Policy and Conflicts of Interest Policy when selecting execution venues.</p>
	<p>Conflicts of interest The Firm has no conflicts of interest to report.</p>	<p>Conflicts of interest Not applicable</p>
	<p>Common ownerships During the period under review certain orders were transmitted to the affiliate firm Citadel Advisors LLC to facilitate execution. These orders related to non-EMEA instruments.</p>	<p>Common ownerships These common ownerships did not influence the Firm's selection of the execution venues as the Firm followed its Best Execution Policy and Conflicts of Interest Policy when selecting execution venues.</p>
Specific arrangements with execution venues¹ regarding payments made or received, discounts, rebates or non-monetary benefits received	<p>During the period under review only research and business gifts and entertainments were received. No payments were made to or received from execution venues except as related to the settlement of transactions. In addition no discounts or rebates were received.</p>	<p>The Firm followed its Compliance Manual and Business Gifts & Entertainment Policy in line with its regulatory obligations in relation to these arrangements. No issues were noted in respect of these non-monetary benefits received. In addition these arrangements did not influence the Firm's selection of execution venues, as the Firm followed its Best Execution Policy and Conflicts of Interest Policy when selecting execution venues.</p>

¹ This report has been produced in line with the requirements of the recast Markets in Financial Instruments Directive and Regulation (together, "MiFID II") and Regulatory Technical Standard ("RTS") 28, as implemented in the UK.

² For the purposes of this report, execution venue means broker, trading venue, systematic internaliser, market maker, liquidity provider and/or third country entity performing a similar function.

Factors leading to a change in the list of execution venues¹ listed in the order execution policy	<p>The list of execution venues referred to in the Firm's Best Execution Policy was changed during the period under review.</p> <p>The following factors led to such change:</p> <ul style="list-style-type: none"> • available liquidity <p>In addition, as a result of the ongoing monitoring of the quality of execution, the allocation of orders to the various execution venues changed throughout the period under review.</p>	The factors leading to such changes were objective factors which were considered and applied by the Firm on an objective basis.
Differentiation across client categories	All of the Firm's clients are professional clients.	Not applicable
Use of data / tools³ relating to quality of execution	<p>The Firm has used the following data and tools relating to quality of execution during the period under review:</p> <ul style="list-style-type: none"> • A regular internal calculation of transaction cost to consider the performance level of the execution venues. • A regular Broker Vote to consider the operational quality of the execution venues. 	These objective factors were considered and applied by the Firm on an objective basis.
Use of consolidated tape provider output	There were no consolidated tape providers during the period under review.	Not applicable
Use of Direct Electronic Access (DEA)	<p>The list of Top 5 execution venues for this class of instrument includes a brokers who provides the Firm with direct electronic access to trading venues.</p> <p>This broker is: Merrill Lynch.</p> <p>The trading venues accessed by the Firm using DEA for this instrument class were: ICE US, ICE Futures Europe, CME and Euronext Matif.</p>	

³ For this report published in 2018, due to the lack of RTS 27 data made available by execution venues, only limited external data has been used by the Firm as anticipated by ESMA in their response to Q6 (p20) of the Q&A on Best Execution (ESMA 35-43-349). For the reports published in 2019 and onwards, RTS 27 data will be incorporated into the evaluation of quality of execution.

ALL TRADEMARKS, SERVICE MARKS AND LOGOS USED IN THIS DOCUMENT ARE TRADEMARKS OR SERVICE MARKS OR REGISTERED TRADEMARKS OR REGISTERED SERVICE MARKS OF CITADEL

NEITHER THIS DOCUMENT NOR ANY OF THE INFORMATION CONTAINED IN IT SHALL CONSTITUTE AN OFFER, SOLICITATION, INVITATION OR INDUCEMENT TO PURCHASE, ACQUIRE, SUBSCRIBE TO, PROVIDE OR SELL ANY PARTICULAR INVESTMENT, NOR DOES IT CONSTITUTE INVESTMENT ADVICE OR ANY OTHER RECOMMENDATION REGARDING ANY PARTICULAR INVESTMENT, NOR SHALL IT OR ANY PART OF IT FORM THE BASIS OF OR BE RELIED UPON AS A PROMISE OR REPRESENTATION IN CONNECTION WITH ANY CONTRACT OR INVESTMENT DECISION.